Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, tolerability and pharmacokinetics of censavudin in healthy male volunteer

Trial Profile

Safety, tolerability and pharmacokinetics of censavudin in healthy male volunteer

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2013

At a glance

  • Drugs Censavudine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Oncolys BioPharma
  • Most Recent Events

    • 10 Feb 2009 Results will be reported at CROI 2008, according to an OSI Pharmaceuticals media release.
    • 10 Feb 2009 Status changed from planning to completed, according to a OSI Pharmaceuticals media release.
    • 22 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top